A major partnership between GE HealthCare and DeepHealth is accelerating the global rollout of AI-powered breast cancer screening tools, marking a significant shift in how hospitals approach mammography. The expanded collaboration, announced at the Society of Breast Imaging Annual Symposium in April 2026, aims to bring advanced artificial intelligence (AI) solutions to breast imaging programs worldwide, building on a joint initiative that began in 2024 .

What Makes This AI Breast Cancer Tool Different?

The partnership centers on DeepHealth's Breast Suite, a cloud-based platform designed to integrate seamlessly into existing mammography workflows. Unlike point-solution tools that handle a single task, Breast Suite combines multiple AI capabilities into one modular system. The expanded collaboration introduces two new components: ProFound Pro, which combines cancer detection with automated breast density assessment, and Safeguard Review, an AI-powered workflow that flags complex cases for secondary review .

The real-world impact is striking. In the largest U.S. analysis of AI-powered breast cancer screening to date, a multistage AI-driven workflow from Breast Suite demonstrated a 21% increase in cancer detection rate compared to standard care. For women with dense breast tissue, the improvement was even more pronounced, with a 23% increase in cancer detection rate . These numbers matter because dense breast tissue can mask tumors on traditional mammograms, making early detection harder for radiologists.

How Does This AI System Actually Work in Clinical Practice?

The Breast Suite operates as an integrated ecosystem rather than a standalone tool. When paired with GE HealthCare's Pristina Via mammography system, the platform provides several interconnected functions:

• Cancer Detection: The AI automatically localizes suspicious lesions and assigns a degree of suspicion score, helping radiologists prioritize cases and work more efficiently across diverse patient populations and breast densities.
• Automated Density Assessment: The system classifies breast density consistently and objectively, supporting diagnostic decisions without requiring manual assessment by radiologists.
• Timely Alerts: The platform notifies clinical sites of potentially suspicious cases within minutes, enabling faster triage and reducing delays in patient communication.
• Cloud-Based Access: Radiologists can access images and AI insights from anywhere, supporting scalable breast imaging programs across multiple sites.
• Prioritized Worklist: The system ranks cases by clinical urgency, helping teams focus on the most critical patients first.

Dr. Meghna Krishnan, owner of URPrecious Imaging in Arizona, described the practical benefits in clinical use. "Pristina Via and Breast Suite have transformed how we approach breast cancer detection," she stated. "The cloud-based viewer gives us instant access to images from anywhere, and the AI tools, like CAD for lesion detection and automated breast density assessment, can help us deliver fast and consistent results. It's not just about speed, it's about confidence. With Breast Suite, our team can make more accurate decisions without workflow disruptions, which ultimately means better care for our patients" .

"Pristina Via and Breast Suite have transformed how we approach breast cancer detection. The cloud-based viewer gives us instant access to images from anywhere, and the AI tools can help us deliver fast and consistent results," said Dr. Meghna Krishnan.

Dr. Meghna Krishnan, Owner, URPrecious Imaging, Arizona

Why Is This Partnership Expanding Now?

The expanded collaboration signals confidence in the technology's real-world performance. GE HealthCare is extending the partnership internationally and adding new AI applications designed specifically for compatibility with its mammography systems. This move reflects a broader industry trend: moving away from isolated AI tools toward integrated platform infrastructure that works within existing clinical workflows .

Jyoti Gupta, President and CEO of Women's Health and X-ray at GE HealthCare, explained the strategic vision. "At GE HealthCare, we're advancing women's health through precision care built around the unique needs of women and enhanced by the power of AI," she said. "By integrating Breast Suite AI with our Pristina Via mammography system, we're helping clinicians detect breast cancer early with greater confidence. These innovations move us closer towards truly personalized prevention and care for women" .

Jyoti Gupta, President and CEO of Women's Health and X-ray at GE HealthCare

"By integrating Breast Suite AI with our Pristina Via mammography system, we're helping clinicians detect breast cancer early with greater confidence. These innovations move us closer towards truly personalized prevention and care for women," said Jyoti Gupta.

Jyoti Gupta, PhD, President and CEO, Women's Health and X-ray at GE HealthCare

Niccolo Stefani, Business Leader for Population Health and Clinical AI at DeepHealth, emphasized the company's broader mission. "Through our expanded collaboration with GE HealthCare, we are bringing the power of our new Breast Suite to providers around the world to enable early cancer detection, deeper clinical insights, and more confident decisions," he noted. "Together we are pushing the boundaries of what mammography can deliver, not only for breast cancer screening but for women's health more broadly" .

Niccolo Stefani, Business Leader for Population Health and Clinical AI at DeepHealth

"Through our expanded collaboration with GE HealthCare, we are bringing the power of our new Breast Suite to providers around the world to enable early cancer detection, deeper clinical insights, and more confident decisions," said Niccolo Stefani.

Niccolo Stefani, MD, Business Leader Population Health and Clinical AI, DeepHealth

What Other AI Innovations Are Being Showcased?

Beyond the Breast Suite expansion, GE HealthCare is introducing complementary AI-powered technologies designed to enhance breast imaging across multiple modalities. Pristina Recon DL is an advanced 3D mammography reconstruction technology powered by deep learning that sets a new standard in image definition and sharpness. The system uses two sequential deep learning models: the first reconstructs high-fidelity 3D volumes while minimizing artifacts and noise, and the second enhances the visualization of clinically relevant information in the synthesized 2D view. Notably, it is the first mammography technology to combine deep learning with iterative reconstruction to deliver outstanding digital breast tomosynthesis (DBT) image quality without compromising patient dose .

The Invenia ABUS (Automated Breast Ultrasound) Prime system represents another advancement. It is the first FDA-approved supplemental screening breast ultrasound indicated as an adjunct to mammography and specifically designed for early cancer detection in women with dense breasts. The Prime version is a scalable, enterprise-ready solution designed for large breast imaging programs and multi-site deployment, with consistent acquisition and efficient workflows when leveraging five or more systems across imaging networks .

What Does This Mean for Patients and Healthcare Systems?

The expansion of AI-powered breast cancer screening has immediate practical implications. Higher detection rates mean more cancers caught at earlier, more treatable stages. The 21% improvement in detection rate translates to approximately one additional cancer detected per 100 screening exams compared to standard care, a meaningful difference at the population level. For healthcare systems, the cloud-based infrastructure and automated workflows reduce radiologist workload and enable scalable screening programs across multiple sites without proportional increases in staffing .

The focus on dense breast tissue is particularly important. Approximately 40% of women have dense breast tissue, which increases both cancer risk and the difficulty of detection on standard mammograms. By automating density assessment and providing AI-assisted lesion detection specifically trained on diverse breast types, these tools help address a significant clinical gap .

As AI-powered breast imaging continues to evolve, the partnership between GE HealthCare and DeepHealth demonstrates how clinical validation, real-world performance data, and strategic collaboration can accelerate adoption of advanced diagnostic tools globally. The expansion signals that AI in breast cancer screening is moving beyond pilot programs and into mainstream clinical practice.